{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=23", "query": { "condition": "Biliary Diseases", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 735, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:39:43.620Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04024813", "title": "A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sclerosing Cholangitis" ], "interventions": [ { "name": "Seladelpar", "type": "DRUG" }, { "name": "Placebo to match Seladelpar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-11-12", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Novi", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024813" }, { "nct_id": "NCT00789958", "title": "S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 105, "start_date": "2008-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 251, "location_summary": "Anniston, Alabama • Little Rock, Arkansas • Berkeley, California + 181 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00789958" }, { "nct_id": "NCT05775159", "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2023-04-24", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775159" }, { "nct_id": "NCT02375880", "title": "Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma of Intrahepatic and Extra-hepatic Biliary System", "Carcinoma of Gallbladder", "Bile Duct Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "DKN-01", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 51, "start_date": "2015-06", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375880" }, { "nct_id": "NCT07146646", "title": "Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer", "Biliary Tract Neoplasms", "Cholangiocarcinoma", "Gallbladder Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "Trifluridine/tipiracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-01", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07146646" }, { "nct_id": "NCT06016842", "title": "A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis (PBC)" ], "interventions": [ { "name": "Elafibranor", "type": "DRUG" }, { "name": "Matched 80 mg placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2023-08-31", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 43, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016842" }, { "nct_id": "NCT07565454", "title": "Evaluation of Hepato-Pancreato-Biliary", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastro-Intestinal Disorder" ], "interventions": [ { "name": "Evaluate and compare the efficacy of our training within the Fellowship Council curriculums", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Methodist Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2021-04-01", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07565454" }, { "nct_id": "NCT00023946", "title": "BMS-247550 in Treating Patients With Liver or Gallbladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Cholangiocellular Carcinoma", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Localized Extrahepatic Bile Duct Cancer", "Localized Gallbladder Cancer", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2001-08", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023946" }, { "nct_id": "NCT05293938", "title": "A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Obeticholic Acid 5 MG", "type": "DRUG" }, { "name": "Obeticholic Acid 10 MG", "type": "DRUG" }, { "name": "Standard of Care: UDCA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-03-28", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293938" }, { "nct_id": "NCT01661114", "title": "A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Biliary Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2011-07", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-10-19", "last_synced_at": "2026-11-15T19:39:43.620Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661114" } ] }